{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T04:16:58Z","timestamp":1792815418148,"version":"4.5.0"},"reference-count":68,"publisher":"American Society of Hematology","issue":"5","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,3,11]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Elevated levels of the NAD+-generating enzyme nicotinamide phosphoribosyltransferase (NAMPT) are a common feature across numerous cancer types. Accordingly, we previously reported pervasive NAD+ dysregulation in multiple myeloma (MM) cells in association with upregulated NAMPT expression. Unfortunately, albeit being effective in preclinical models of cancer, NAMPT inhibition has proven ineffective in clinical trials because of the existence of alternative NAD+ production routes using NAD+ precursors other than nicotinamide. Here, by leveraging mathematical modeling approaches integrated with transcriptome data, we defined the specific NAD+ landscape of MM cells and established that the Preiss-Handler pathway for NAD+ biosynthesis, which uses nicotinic acid as a precursor, supports NAD+ synthesis in MM cells via its key enzyme nicotinate phosphoribosyltransferase (NAPRT). Accordingly, we found that NAPRT confers resistance to NAD+-depleting agents. Transcriptomic, metabolic, and bioenergetic profiling of NAPRT-knockout (KO) MM cells showed these to have weakened endogenous antioxidant defenses, increased propensity to oxidative stress, and enhanced genomic instability. Concomitant NAMPT inhibition further compounded the effects of NAPRT-KO, effectively sensitizing MM cells to the chemotherapeutic drug, melphalan; NAPRT added-back fully rescues these phenotypes. Overall, our results propose comprehensive NAD+ biosynthesis inhibition, through simultaneously targeting NAMPT and NAPRT, as a promising strategy to be tested in randomized clinical trials involving transplant-eligible patients with MM, especially those with more aggressive disease.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024013425","type":"journal-article","created":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T22:01:28Z","timestamp":1733954488000},"page":"1024-1039","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":7,"title":["NAD+ metabolism restriction boosts high-dose melphalan efficacy in patients with multiple myeloma"],"prefix":"10.1182","volume":"9","author":[{"given":"Debora","family":"Soncini","sequence":"first","affiliation":[{"name":"1IRCCS Ospedale Policlinico San Martino, Genoa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Becherini","sequence":"additional","affiliation":[{"name":"2Clinic of Hematology, Department of Internal Medicine and Medical Specialties, University of Genoa, Genoa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-2868-739X","authenticated-orcid":false,"given":"Francesco","family":"Ladisa","sequence":"additional","affiliation":[{"name":"2Clinic of Hematology, Department of Internal Medicine and Medical Specialties, University of Genoa, Genoa, Italy"},{"name":"3Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0803-1042","authenticated-orcid":false,"given":"Silvia","family":"Ravera","sequence":"additional","affiliation":[{"name":"1IRCCS Ospedale Policlinico San Martino, Genoa, Italy"},{"name":"4Department of Experimental Medicine, University of Genoa, Genoa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7884-6434","authenticated-orcid":false,"given":"Adithya","family":"Chedere","sequence":"additional","affiliation":[{"name":"5Biological Science Division, Department of Biochemistry, Indian Institute of Science, Bengaluru, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1673-4039","authenticated-orcid":false,"given":"Elisa","family":"Gelli","sequence":"additional","affiliation":[{"name":"6Genetics and Epigenetics of Behavior Laboratory, Fondazione Istituto Italiano di Tecnologia, Genoa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-7494-0154","authenticated-orcid":false,"given":"Giulia","family":"Giorgetti","sequence":"additional","affiliation":[{"name":"2Clinic of Hematology, Department of Internal Medicine and Medical Specialties, University of Genoa, Genoa, Italy"},{"name":"3Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7388-188X","authenticated-orcid":false,"given":"Claudia","family":"Martinuzzi","sequence":"additional","affiliation":[{"name":"1IRCCS Ospedale Policlinico San Martino, Genoa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Piacente","sequence":"additional","affiliation":[{"name":"4Department of Experimental Medicine, University of Genoa, Genoa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Mastracci","sequence":"additional","affiliation":[{"name":"1IRCCS Ospedale Policlinico San Martino, Genoa, Italy"},{"name":"7Department of Integrated Surgical and Diagnostic Sciences, University of Genoa, Genoa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Veneziano","sequence":"additional","affiliation":[{"name":"8Department of Experimental and Clinical Medicine, University Magna Graecia of Catanzaro, Catanzaro, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Santamaria","sequence":"additional","affiliation":[{"name":"8Department of Experimental and Clinical Medicine, University Magna Graecia of Catanzaro, Catanzaro, Italy"},{"name":"9First Department of Medicine, Cardiology, Klinikum rechts der Isar, Technical University of Munich, School of Medicine and Health, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4303-7252","authenticated-orcid":false,"given":"Fiammetta","family":"Monacelli","sequence":"additional","affiliation":[{"name":"10Geriatrics Clinic, Department of Internal Medicine and Medical Specialties, University of Genoa, Genoa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-5411-2660","authenticated-orcid":false,"given":"Moustafa S.","family":"Ghanem","sequence":"additional","affiliation":[{"name":"10Geriatrics Clinic, Department of Internal Medicine and Medical Specialties, University of Genoa, Genoa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonia","family":"Cagnetta","sequence":"additional","affiliation":[{"name":"1IRCCS Ospedale Policlinico San Martino, Genoa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Guolo","sequence":"additional","affiliation":[{"name":"1IRCCS Ospedale Policlinico San Martino, Genoa, Italy"},{"name":"2Clinic of Hematology, Department of Internal Medicine and Medical Specialties, University of Genoa, Genoa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Garibotto","sequence":"additional","affiliation":[{"name":"2Clinic of Hematology, Department of Internal Medicine and Medical Specialties, University of Genoa, Genoa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8494-0627","authenticated-orcid":false,"given":"Sara","family":"Aquino","sequence":"additional","affiliation":[{"name":"11Hematology and Hematopoietic Stem Cell Transplantation Unit, IRCCS Ospedale Policlinico San Martino, Genoa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Passalaqua","sequence":"additional","affiliation":[{"name":"4Department of Experimental Medicine, University of Genoa, Genoa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santina","family":"Bruzzone","sequence":"additional","affiliation":[{"name":"1IRCCS Ospedale Policlinico San Martino, Genoa, Italy"},{"name":"4Department of Experimental Medicine, University of Genoa, Genoa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Bellotti","sequence":"additional","affiliation":[{"name":"12Service and Central Laboratory of Hematology, Departments of Oncology and Medical Laboratory and Pathology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0543-3449","authenticated-orcid":false,"given":"Michel A.","family":"Duchosal","sequence":"additional","affiliation":[{"name":"12Service and Central Laboratory of Hematology, Departments of Oncology and Medical Laboratory and Pathology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4968-3167","authenticated-orcid":false,"given":"Aimable","family":"Nahimana","sequence":"additional","affiliation":[{"name":"12Service and Central Laboratory of Hematology, Departments of Oncology and Medical Laboratory and Pathology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6512-6080","authenticated-orcid":false,"given":"Emanuele","family":"Angelucci","sequence":"additional","affiliation":[{"name":"11Hematology and Hematopoietic Stem Cell Transplantation Unit, IRCCS Ospedale Policlinico San Martino, Genoa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9939-8439","authenticated-orcid":false,"given":"Chandra","family":"Nagasuma","sequence":"additional","affiliation":[{"name":"5Biological Science Division, Department of Biochemistry, Indian Institute of Science, Bengaluru, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessio","family":"Nencioni","sequence":"additional","affiliation":[{"name":"1IRCCS Ospedale Policlinico San Martino, Genoa, Italy"},{"name":"10Geriatrics Clinic, Department of Internal Medicine and Medical Specialties, University of Genoa, Genoa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto Massimo","family":"Lemoli","sequence":"additional","affiliation":[{"name":"1IRCCS Ospedale Policlinico San Martino, Genoa, Italy"},{"name":"2Clinic of Hematology, Department of Internal Medicine and Medical Specialties, University of Genoa, Genoa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1530-6729","authenticated-orcid":false,"given":"Michele","family":"Cea","sequence":"additional","affiliation":[{"name":"1IRCCS Ospedale Policlinico San Martino, Genoa, Italy"},{"name":"2Clinic of Hematology, Department of Internal Medicine and Medical Specialties, University of Genoa, Genoa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,2,27]]},"reference":[{"issue":"3","key":"2025032513475291500_bib1","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1111\/bjh.16674","article-title":"Incidence and survival of multiple myeloma: a population-based study of 10 524 patients diagnosed 1982-2017","volume":"191","author":"Langseth","year":"2020","journal-title":"Br J Haematol"},{"issue":"11","key":"2025032513475291500_bib2","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1056\/NEJMra1011442","article-title":"Multiple myeloma","volume":"364","author":"Palumbo","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"2025032513475291500_bib3","doi-asserted-by":"crossref","first-page":"17046","DOI":"10.1038\/nrdp.2017.46","article-title":"Multiple myeloma","volume":"3","author":"Kumar","year":"2017","journal-title":"Nat Rev Dis Primers"},{"issue":"10272","key":"2025032513475291500_bib4","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/S0140-6736(21)00135-5","article-title":"Multiple myeloma","volume":"397","author":"van de Donk","year":"2021","journal-title":"Lancet"},{"issue":"10396","key":"2025032513475291500_bib5","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/S0140-6736(23)00521-4","article-title":"T-cell-engaging bispecific antibodies in cancer","volume":"402","author":"van de Donk","year":"2023","journal-title":"Lancet"},{"issue":"3","key":"2025032513475291500_bib6","doi-asserted-by":"crossref","first-page":"e105","DOI":"10.1016\/S1470-2045(20)30756-7","article-title":"Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group","volume":"22","author":"Moreau","year":"2021","journal-title":"Lancet Oncol"},{"issue":"5","key":"2025032513475291500_bib7","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1038\/s41375-022-01531-2","article-title":"LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and\/or refractory multiple myeloma","volume":"36","author":"Mateos","year":"2022","journal-title":"Leukemia"},{"issue":"13","key":"2025032513475291500_bib8","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1182\/blood.2019001034","article-title":"Amino acid metabolism in hematologic malignancies and the era of targeted therapy","volume":"134","author":"Tabe","year":"2019","journal-title":"Blood"},{"issue":"3","key":"2025032513475291500_bib9","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.cmet.2022.01.007","article-title":"The hallmarks of cancer metabolism: Still emerging","volume":"34","author":"Pavlova","year":"2022","journal-title":"Cell Metab"},{"issue":"9","key":"2025032513475291500_bib10","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/nrendo.2015.117","article-title":"Physiological and pathophysiological roles of NAMPT and NAD metabolism","volume":"11","author":"Garten","year":"2015","journal-title":"Nat Rev Endocrinol"},{"key":"2025032513475291500_bib11","doi-asserted-by":"crossref","first-page":"622","DOI":"10.3389\/fonc.2018.00622","article-title":"NAD metabolism in cancer therapeutics","volume":"8","author":"Yaku","year":"2018","journal-title":"Front Oncol"},{"issue":"1","key":"2025032513475291500_bib12","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/s41392-020-00311-7","article-title":"NAD+ metabolism: pathophysiologic mechanisms and therapeutic potential","volume":"5","author":"Xie","year":"2020","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"2025032513475291500_bib13","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/s41392-020-00354-w","article-title":"NAD+ metabolism, stemness, the immune response, and cancer","volume":"6","author":"Navas","year":"2021","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"2025032513475291500_bib14","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1158\/1078-0432.CCR-18-1776","article-title":"Dual PAK4-NAMPT inhibition impacts growth and survival, and increases sensitivity to DNA-damaging agents in Waldenstr\u00f6m macroglobulinemia","volume":"25","author":"Li","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"24","key":"2025032513475291500_bib15","doi-asserted-by":"crossref","first-page":"6099","DOI":"10.1158\/1078-0432.CCR-16-0630","article-title":"Dual NAMPT and BTK targeting leads to synergistic killing of Waldenstr\u00f6m macroglobulinemia cells regardless of MYD88 and CXCR4 somatic mutation status","volume":"22","author":"Cea","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"7","key":"2025032513475291500_bib16","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1182\/blood-2013-02-483511","article-title":"Intracellular NAD+ depletion enhances bortezomib-induced anti-myeloma activity","volume":"122","author":"Cagnetta","year":"2013","journal-title":"Blood"},{"issue":"17","key":"2025032513475291500_bib17","doi-asserted-by":"crossref","first-page":"3519","DOI":"10.1182\/blood-2012-03-416776","article-title":"Targeting NAD+ salvage pathway induces autophagy in multiple myeloma cells via mTORC1 and extracellular signal-regulated kinase (ERK1\/2) inhibition","volume":"120","author":"Cea","year":"2012","journal-title":"Blood"},{"issue":"6","key":"2025032513475291500_bib18","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.exphem.2013.02.008","article-title":"NAMPT\/PBEF1 enzymatic activity is indispensable for myeloma cell growth and osteoclast activity","volume":"41","author":"Venkateshaiah","year":"2013","journal-title":"Exp Hematol"},{"issue":"14","key":"2025032513475291500_bib19","doi-asserted-by":"crossref","first-page":"3857","DOI":"10.1158\/0008-5472.CAN-16-3079","article-title":"Nicotinic acid phosphoribosyltransferase regulates cancer cell metabolism, susceptibility to NAMPT inhibitors, and DNA repair","volume":"77","author":"Piacente","year":"2017","journal-title":"Cancer Res"},{"issue":"7757","key":"2025032513475291500_bib20","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1038\/s41586-019-1150-2","article-title":"NAD metabolic dependency in cancer is shaped by gene amplification and enhancer remodelling","volume":"569","author":"Chowdhry","year":"2019","journal-title":"Nature"},{"issue":"6","key":"2025032513475291500_bib21","doi-asserted-by":"crossref","first-page":"637","DOI":"10.2174\/1389450111314060003","article-title":"Nicotinamide phosphoribosyltransferase (NAMPT) inhibitors as therapeutics: rationales, controversies, clinical experience","volume":"14","author":"Montecucco","year":"2013","journal-title":"Curr Drug Targets"},{"issue":"3","key":"2025032513475291500_bib22","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/leu.2017.281","article-title":"Targeting the vulnerability to NAD+ depletion in B-cell acute lymphoblastic leukemia","volume":"32","author":"Takao","year":"2018","journal-title":"Leukemia"},{"issue":"2","key":"2025032513475291500_bib23","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1182\/blood-2018-05-850826","article-title":"IDH2 inhibition enhances proteasome inhibitor responsiveness in hematological malignancies","volume":"133","author":"Bergaggio","year":"2019","journal-title":"Blood"},{"issue":"3","key":"2025032513475291500_bib24","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1182\/bloodadvances.2018024182","article-title":"Selective targeting of NAMPT by KPT-9274 in acute myeloid leukemia","volume":"3","author":"Mitchell","year":"2019","journal-title":"Blood Adv"},{"issue":"8","key":"2025032513475291500_bib25","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1158\/1078-0432.CCR-20-3724","article-title":"Targeting DNA damage repair functions of two histone deacetylases, HDAC8 and SIRT6, sensitizes acute myeloid leukemia to NAMPT inhibition","volume":"27","author":"Zhang","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"17","key":"2025032513475291500_bib26","doi-asserted-by":"crossref","first-page":"3934","DOI":"10.1158\/1078-0432.CCR-14-3023","article-title":"APO866 increases antitumor activity of cyclosporin-a by inducing mitochondrial and endoplasmic reticulum stress in leukemia cells","volume":"21","author":"Cagnetta","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"4","key":"2025032513475291500_bib27","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1038\/s41419-022-04763-3","article-title":"Gut microbiota severely hampers the efficacy of NAD-lowering therapy in leukemia","volume":"13","author":"ElMokh","year":"2022","journal-title":"Cell Death Dis"},{"issue":"1","key":"2025032513475291500_bib28","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.cmet.2015.05.023","article-title":"NAD(+) metabolism and the control of energy homeostasis: a balancing act between mitochondria and the nucleus","volume":"22","author":"Cant\u00f3","year":"2015","journal-title":"Cell Metab"},{"issue":"11","key":"2025032513475291500_bib29","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/nrc3340","article-title":"The NAD metabolome--a key determinant of cancer cell biology","volume":"12","author":"Chiarugi","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"2025032513475291500_bib30","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1146\/annurev.nutr.28.061807.155443","article-title":"Nicotinic acid, nicotinamide, and nicotinamide riboside: a molecular evaluation of NAD+ precursor vitamins in human nutrition","volume":"28","author":"Bogan","year":"2008","journal-title":"Annu Rev Nutr"},{"issue":"7731","key":"2025032513475291500_bib31","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/s41586-018-0645-6","article-title":"De novo NAD+ synthesis enhances mitochondrial function and improves health","volume":"563","author":"Katsyuba","year":"2018","journal-title":"Nature"},{"issue":"6","key":"2025032513475291500_bib32","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.ccell.2015.11.006","article-title":"Extreme Vulnerability of IDH1 mutant cancers to NAD+ depletion","volume":"28","author":"Tateishi","year":"2015","journal-title":"Cancer Cell"},{"key":"2025032513475291500_bib33","doi-asserted-by":"crossref","first-page":"954512","DOI":"10.3389\/fonc.2022.954512","article-title":"Personalized quantitative models of NAD metabolism in hepatocellular carcinoma identify a subgroup with poor prognosis","volume":"12","author":"Chedere","year":"2022","journal-title":"Front Oncol"},{"issue":"1","key":"2025032513475291500_bib34","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41408-024-00978-z","article-title":"Translocation t(14;16) in multiple myeloma: gangster or just part of the gang?","volume":"14","author":"Mian","year":"2024","journal-title":"Blood Cancer J"},{"issue":"4","key":"2025032513475291500_bib35","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.3390\/molecules28041897","article-title":"Anticancer activities of novel nicotinamide phosphoribosyltransferase inhibitors in hematological malignancies","volume":"28","author":"Biniecka","year":"2023","journal-title":"Molecules"},{"issue":"1","key":"2025032513475291500_bib36","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1158\/1078-0432.CCR-13-0150","article-title":"Targeting of NAD metabolism in pancreatic cancer cells: potential novel therapy for pancreatic tumors","volume":"20","author":"Chini","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"11","key":"2025032513475291500_bib37","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1158\/1541-7786.MCR-17-0526","article-title":"CD38 inhibits prostate cancer metabolism and proliferation by reducing cellular NAD+ pools","volume":"16","author":"Chmielewski","year":"2018","journal-title":"Mol Cancer Res"},{"issue":"7","key":"2025032513475291500_bib38","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1038\/s41375-019-0692-5","article-title":"OT-82, a novel anticancer drug candidate that targets the strong dependence of hematological malignancies on NAD biosynthesis","volume":"34","author":"Korotchkina","year":"2020","journal-title":"Leukemia"},{"issue":"14","key":"2025032513475291500_bib39","doi-asserted-by":"crossref","first-page":"3276","DOI":"10.1182\/blood-2008-08-173369","article-title":"The NAD biosynthesis inhibitor APO866 has potent antitumor activity against hematologic malignancies","volume":"113","author":"Nahimana","year":"2009","journal-title":"Blood"},{"issue":"3","key":"2025032513475291500_bib40","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.cmet.2020.02.001","article-title":"Bacteria boost mammalian host NAD metabolism by engaging the deamidated biosynthesis pathway","volume":"31","author":"Shats","year":"2020","journal-title":"Cell Metab"},{"issue":"1","key":"2025032513475291500_bib41","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s00394-015-1079-7","article-title":"Micronutrient status and intake in omnivores, vegetarians and vegans in Switzerland","volume":"56","author":"Sch\u00fcpbach","year":"2017","journal-title":"Eur J Nutr"},{"key":"2025032513475291500_bib42","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.abb.2014.09.008","article-title":"A\u00a0pre-steady state and steady state kinetic analysis of the N-ribosyl hydrolase activity of hCD157","volume":"564","author":"Preugschat","year":"2014","journal-title":"Arch Biochem Biophys"},{"issue":"1","key":"2025032513475291500_bib43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40170-018-0174-7","article-title":"Cancer cell metabolic plasticity allows resistance to NAMPT inhibition but invariably induces dependence on LDHA","volume":"6","author":"Thongon","year":"2018","journal-title":"Cancer Metab"},{"issue":"1","key":"2025032513475291500_bib44","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/s41467-017-02391-6","article-title":"Perturbation-response genes reveal signaling footprints in cancer gene expression","volume":"9","author":"Schubert","year":"2018","journal-title":"Nat Commun"},{"issue":"19","key":"2025032513475291500_bib45","doi-asserted-by":"crossref","first-page":"16639","DOI":"10.1074\/jbc.M200360200","article-title":"NF-\u03baB as a therapeutic target in multiple myeloma","volume":"277","author":"Hideshima","year":"2002","journal-title":"J\u00a0Biol Chem"},{"issue":"1","key":"2025032513475291500_bib46","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/cr.2010.178","article-title":"Crosstalk of reactive oxygen species and NF-\u03baB signaling","volume":"21","author":"Morgan","year":"2011","journal-title":"Cell Res"},{"issue":"62","key":"2025032513475291500_bib47","doi-asserted-by":"crossref","first-page":"6723","DOI":"10.18632\/oncotarget.27336","article-title":"Reactive oxygen\/nitrogen species contribute substantially to the antileukemia effect of APO866, a NAD lowering agent","volume":"10","author":"Cloux","year":"2019","journal-title":"Oncotarget"},{"issue":"34","key":"2025032513475291500_bib48","doi-asserted-by":"crossref","first-page":"24574","DOI":"10.1074\/jbc.M610357200","article-title":"Elevation of cellular NAD levels by nicotinic acid and involvement of nicotinic acid phosphoribosyltransferase in human cells","volume":"282","author":"Hara","year":"2007","journal-title":"J\u00a0Biol Chem"},{"issue":"6771","key":"2025032513475291500_bib49","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1038\/35001622","article-title":"Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase","volume":"403","author":"Imai","year":"2000","journal-title":"Nature"},{"issue":"1","key":"2025032513475291500_bib50","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s42255-019-0161-5","article-title":"NAD+ homeostasis in health and disease","volume":"2","author":"Katsyuba","year":"2020","journal-title":"Nat Metab"},{"issue":"9","key":"2025032513475291500_bib51","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1158\/2159-8290.CD-14-0943","article-title":"Synthetic lethal approaches exploiting DNA damage in aggressive myeloma","volume":"5","author":"Cottini","year":"2015","journal-title":"Cancer Discov"},{"issue":"1","key":"2025032513475291500_bib52","doi-asserted-by":"crossref","first-page":"80","DOI":"10.3324\/haematol.2017.176248","article-title":"Depletion of SIRT6 enzymatic activity increases acute myeloid leukemia cells\u2019 vulnerability to DNA-damaging agents","volume":"103","author":"Cagnetta","year":"2018","journal-title":"Haematologica"},{"issue":"9","key":"2025032513475291500_bib53","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1182\/blood-2015-06-649970","article-title":"Evidence for a role of the histone deacetylase SIRT6 in DNA damage response of multiple myeloma cells","volume":"127","author":"Cea","year":"2016","journal-title":"Blood"},{"issue":"6","key":"2025032513475291500_bib54","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1007\/s00280-009-1125-3","article-title":"Safety and efficacy of NAD depleting cancer drugs: results of a phase I clinical trial of CHS 828 and overview of published data","volume":"65","author":"Von Heideman","year":"2010","journal-title":"Cancer Chemother Pharmacol"},{"issue":"7","key":"2025032513475291500_bib55","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1001\/jamadermatol.2016.0401","article-title":"Efficacy and safety of APO866 in patients with refractory or relapsed cutaneous T-cell lymphoma: a phase 2 clinical trial","volume":"152","author":"Goldinger","year":"2016","journal-title":"JAMA Dermatol"},{"issue":"3","key":"2025032513475291500_bib56","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1038\/s41375-020-0962-2","article-title":"The mevalonate pathway is an actionable vulnerability of t(4;14)-positive multiple myeloma","volume":"35","author":"Longo","year":"2021","journal-title":"Leukemia"},{"issue":"3","key":"2025032513475291500_bib57","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1182\/blood.2023022859","article-title":"NSD2 drives t(4;14) myeloma cell dependence on adenylate kinase 2 by diverting one-carbon metabolism to the epigenome","volume":"144","author":"Sobh","year":"2024","journal-title":"Blood"},{"issue":"6","key":"2025032513475291500_bib58","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1182\/blood-2005-11-013458","article-title":"The molecular classification of multiple myeloma","volume":"108","author":"Zhan","year":"2006","journal-title":"Blood"},{"issue":"6","key":"2025032513475291500_bib59","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.cmet.2014.10.008","article-title":"DNA damage response and metabolic disease","volume":"20","author":"Shimizu","year":"2014","journal-title":"Cell Metab"},{"issue":"4","key":"2025032513475291500_bib60","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1172\/JCI90277","article-title":"DNA repair deficiency sensitizes lung cancer cells to NAD+ biosynthesis blockade","volume":"128","author":"Touat","year":"2018","journal-title":"J\u00a0Clin Invest"},{"issue":"1","key":"2025032513475291500_bib61","doi-asserted-by":"crossref","first-page":"8095","DOI":"10.1038\/s41467-023-43630-3","article-title":"Niacin restriction with NAMPT-inhibition is synthetic lethal to neuroendocrine carcinoma","volume":"14","author":"Nomura","year":"2023","journal-title":"Nat Commun"},{"issue":"1","key":"2025032513475291500_bib62","doi-asserted-by":"crossref","first-page":"6767","DOI":"10.1038\/s41467-021-27080-3","article-title":"BST1 regulates nicotinamide riboside metabolism via its glycohydrolase and base-exchange activities","volume":"12","author":"Yaku","year":"2021","journal-title":"Nat Commun"},{"issue":"1","key":"2025032513475291500_bib63","doi-asserted-by":"crossref","first-page":"5818","DOI":"10.1038\/s41467-023-41372-w","article-title":"NAD+ metabolism is a key modulator of bacterial respiratory epithelial infections","volume":"14","author":"Klabunde","year":"2023","journal-title":"Nat Commun"},{"issue":"6161","key":"2025032513475291500_bib64","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1126\/science.1240537","article-title":"The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide","volume":"342","author":"Viaud","year":"2013","journal-title":"Science"},{"key":"2025032513475291500_bib65","doi-asserted-by":"crossref","first-page":"14554","DOI":"10.1038\/srep14554","article-title":"Local bacteria affect the efficacy of chemotherapeutic drugs","volume":"5","author":"Lehouritis","year":"2015","journal-title":"Sci Rep"},{"issue":"6161","key":"2025032513475291500_bib66","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1126\/science.1240527","article-title":"Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment","volume":"342","author":"Iida","year":"2013","journal-title":"Science"},{"issue":"12","key":"2025032513475291500_bib67","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1001\/jamaoncol.2019.2785","article-title":"Association of prior antibiotic treatment with survival and response to immune checkpoint inhibitor therapy in patients with cancer","volume":"5","author":"Pinato","year":"2019","journal-title":"JAMA Oncol"},{"issue":"12","key":"2025032513475291500_bib68","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1016\/S1470-2045(19)30506-6","article-title":"Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial","volume":"20","author":"Drayson","year":"2019","journal-title":"Lancet Oncol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/5\/1024\/2357200\/blooda_adv-2024-013425-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/5\/1024\/2357200\/blooda_adv-2024-013425-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T01:01:18Z","timestamp":1742950878000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/5\/1024\/534577\/NAD-metabolism-restriction-boosts-high-dose"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,27]]},"references-count":68,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,3,11]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024013425","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,27]]}}}